| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 03/22/2001 | CA2384081A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 03/22/2001 | CA2383402A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 03/22/2001 | CA2383184A1 A process for the preparation of h-tyr-d-ala-phe(f)-phe-nh2 |
| 03/22/2001 | CA2383177A1 Human g-protein coupled receptor |
| 03/22/2001 | CA2383026A1 Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| 03/22/2001 | CA2382633A1 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | CA2381006A1 Antisense modulation of transforming growth factor-.beta. expression |
| 03/22/2001 | CA2350675A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 03/21/2001 | EP1084241A1 G-protein coupled receptor, named 2871 receptor |
| 03/21/2001 | EP1084119A1 Aromatic amine derivatives as pharmaceutical agents |
| 03/21/2001 | EP1084113A1 A process for the preparation of macrocyclic metalloprotease inhibitors |
| 03/21/2001 | EP1084109A1 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 03/21/2001 | EP1084104A1 Nitric oxide synthase inhibitors |
| 03/21/2001 | EP1083928A1 Method of inhibiting angiogenesis and tumor growth and preventing tumor growth and metastases |
| 03/21/2001 | EP1083909A1 hCEPR RECEPTOR |
| 03/21/2001 | EP1083906A1 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue |
| 03/21/2001 | EP1083903A1 Bridged indenopyrrolocarbazoles |
| 03/21/2001 | EP1083902A1 Novel galenic formulations of meloxicam for oral administration |
| 03/21/2001 | EP1083898A1 Novel use of hiv protease inhibiting compounds |
| 03/21/2001 | EP1083891A1 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 03/21/2001 | EP1083890A1 N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use |
| 03/21/2001 | EP1083886A1 Drug delivery system comprising a tightly compacted solid medicament stock |
| 03/21/2001 | EP0717616B1 Process for conditioning substances |
| 03/21/2001 | CN1288468A Antibodies against human IL-12 |
| 03/21/2001 | CN1288464A 4-(2-keto-1-benzimidazolynyl) pipeidine compounds as ORL-1 receptor |
| 03/21/2001 | CN1288457A Inhibitors of & alpha; 4 mediated cell adhesion |
| 03/21/2001 | CN1288382A Sea cucumber carotenoid lipid fraction products and method of use |
| 03/21/2001 | CN1288378A Celecoxib compositions |
| 03/21/2001 | CN1288008A Sulfur-bearing phospho acid compound, pharmaceutical composite and use in prepn. of medicine |
| 03/21/2001 | CN1287850A Prescription of external use paste made of Chinese herb medicine for treating vascular headache |
| 03/21/2001 | CN1287849A Traditional Chinese medicine for expelling wind and removing dampness |
| 03/21/2001 | CN1063444C Stable crystalline (65)-and (GR)-tetrahydrofolic acid |
| 03/20/2001 | US6204371 Compositions and methods for the treatment and diagnosis of immune disorders |
| 03/20/2001 | US6204290 Treating a hypercholesteremic, thrombotic, oxidative, inflammatory, or immunoregulatory disease |
| 03/20/2001 | US6204273 Treatment of androgenic sensitive disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness, and benign prostatic hyperplasia. |
| 03/20/2001 | US6204266 Pharmaceutical, cosmetic and/or food composition having anti-oxidant properties |
| 03/20/2001 | US6204261 Inhibitors of interleukin-1β Converting enzyme inhibitors |
| 03/20/2001 | US6204242 Method for treating rheumatoid arthritis with composition containing histone |
| 03/20/2001 | US6204055 Antisense inhibition of Fas mediated signaling |
| 03/20/2001 | US6204022 Low-toxicity human interferon-alpha analogs |
| 03/20/2001 | US6204007 Antibodies against E-selectin |
| 03/20/2001 | US6203790 Genetic engineering; antiinflammatory agents |
| 03/20/2001 | CA2206287C Aryl thioxanthines |
| 03/20/2001 | CA2199128C Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
| 03/20/2001 | CA2070169C Compounds with a sequence of three radicals, the central one being -aminoacidic and therapeutical applications thereof |
| 03/20/2001 | CA1341207C Analogues of insulin-like growth factor-1 |
| 03/15/2001 | WO2001018236A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 03/15/2001 | WO2001018204A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 03/15/2001 | WO2001018176A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | WO2001018172A2 Fibroblast growth factor-like polypeptides |
| 03/15/2001 | WO2001018125A1 Synthetic vegetal melanins, process for their production and compositions containing thereof |
| 03/15/2001 | WO2001018051A2 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| 03/15/2001 | WO2001018049A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | WO2001018042A2 Apoptosis proteins |
| 03/15/2001 | WO2001018024A1 Antisense modulation of x-linked inhibitor of apoptosis expression |
| 03/15/2001 | WO2001018023A1 Antisense modulation of pi3 kinase p110 beta expression |
| 03/15/2001 | WO2001018021A1 B7-like polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | WO2001018013A1 Prodrugs for liver specific drug delivery |
| 03/15/2001 | WO2001017996A1 1,2,3-thiadiazoles and their use as cox-2 inhibitors |
| 03/15/2001 | WO2001017995A1 Tyrosine kinase inhibitors |
| 03/15/2001 | WO2001017986A1 Compositions and therapeutic methods involving isoflavones and analogues thereof |
| 03/15/2001 | WO2001017959A2 Vitronectin receptor antagonists |
| 03/15/2001 | WO2001017614A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 03/15/2001 | WO2001017596A1 Method of treating cardio pulmonary diseases with no group compounds |
| 03/15/2001 | WO2001017568A2 Bioconjugation in vivo to pulmonary or blood components |
| 03/15/2001 | WO2001017558A2 Novel uses of mammalian ccr6 receptors and related reagents |
| 03/15/2001 | WO2001017546A1 Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| 03/15/2001 | WO2001017532A1 Human neuropeptide receptor |
| 03/15/2001 | WO2001017508A1 Cationic liposome delivery of taxanes to angiogenic blood vessels |
| 03/15/2001 | WO2001017472A1 Using quaternary ammonium salts for transdermal drug delivery |
| 03/15/2001 | WO2000078779A3 N-pyrazole a2a receptor agonists |
| 03/15/2001 | WO2000077198A3 Identification and molecular characterisation of proteins, expressed in the tick salivary glands |
| 03/15/2001 | WO2000075127A8 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof |
| 03/15/2001 | WO2000075113A8 Novel heterocyclic carboxamide derivatives |
| 03/15/2001 | WO2000074678A8 Analgesics |
| 03/15/2001 | WO2000061609A3 Prodrugs of thrombin inhibitors |
| 03/15/2001 | WO2000061604A3 Pharmaceutical compounds |
| 03/15/2001 | WO2000059469A3 Endodontic fibers and methods of use therefor |
| 03/15/2001 | WO2000013648B1 Method for the preparation of citalopram |
| 03/15/2001 | DE19940944A1 Retardierte, orale, pharmazeutische Darreichungsformen Prolonged-release oral pharmaceutical dosage forms |
| 03/15/2001 | CA2389916A1 B7-like polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | CA2388562A1 Mammalian cytokines; related reagents and methods |
| 03/15/2001 | CA2384679A1 Using quaternary ammonium salts for transdermal drug delivery |
| 03/15/2001 | CA2384672A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | CA2384671A1 Vitronectin receptor antagonists |
| 03/15/2001 | CA2384650A1 Apoptosis proteins |
| 03/15/2001 | CA2384456A1 Antisense modulation of x-linked inhibitor of apoptosis expression |
| 03/15/2001 | CA2384101A1 Tyrosine kinase inhibitors |
| 03/15/2001 | CA2384099A1 Compositions and therapeutic methods involving isoflavones and analogues thereof |
| 03/15/2001 | CA2384083A1 Human neuropeptide receptor |
| 03/15/2001 | CA2384076A1 Novel uses of mammalian ccr6 receptors and related reagents |
| 03/15/2001 | CA2383932A1 Synthetic vegetal melanins, process for their production and compositions containing thereof |
| 03/15/2001 | CA2383798A1 Pulmonary delivery for bioconjugation |
| 03/15/2001 | CA2383794A1 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 03/15/2001 | CA2383790A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 03/15/2001 | CA2383788A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 03/15/2001 | CA2383774A1 Fibroblast growth factor-like polypeptides |
| 03/15/2001 | CA2382161A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 03/14/2001 | EP1083171A1 Pyrazoline derivatives, their preparation and application as medicaments |
| 03/14/2001 | EP1082962A1 UTILIZATION OF 2-HYDROXY-4-TRIFLUOROMETHYLBENZO C ACID DERIVATIVES AS INHIBITORS OF THE ACTIVATION OF THE NUCLEAR TRANSCRIPTION FACTORS NF-$g(k)B |